iShares 1-3 Year International TrsBd ETF (ISHG) At $82.11 Forms Top; Shorts at Quest Diagnostics (DGX) Lowered By 5.08%

Quest Diagnostics Incorporated (NYSE:DGX) Logo

iShares 1-3 Year International TrsBd ETF (ISHG) formed multiple top with $88.68 target or 8.00% above today’s $82.11 share price. iShares 1-3 Year International TrsBd ETF (ISHG) has $87.02M valuation. The ETF decreased 0.11% or $0.09 during the last trading session, reaching $82.11. About 901 shares traded. iShares 1-3 Year International TrsBd ETF (NASDAQ:ISHG) has risen 4.17% since June 20, 2017 and is uptrending. It has underperformed by 8.40% the S&P500.

Quest Diagnostics Incorporated (NYSE:DGX) had a decrease of 5.08% in short interest. DGX’s SI was 5.10 million shares in June as released by FINRA. Its down 5.08% from 5.38 million shares previously. With 872,400 avg volume, 6 days are for Quest Diagnostics Incorporated (NYSE:DGX)’s short sellers to cover DGX’s short positions. The SI to Quest Diagnostics Incorporated’s float is 3.76%. The stock increased 0.29% or $0.32 during the last trading session, reaching $110.67. About 632,632 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 2.15% since June 20, 2017 and is downtrending. It has underperformed by 14.72% the S&P500. Some Historical DGX News: ; 14/05/2018 – Quest Diagnostics Declares Quarterly Cash Dividend; 09/03/2018 – Quest Diagnostics Forms Golden Cross: Technicals; 07/05/2018 – Forbes Names Quest Diagnostics One of America’s Best Large Employers; 23/05/2018 – Physicians Lack the Time and Tools to Discover Hidden Risks in Patients with Chronic Conditions, Finds Study from Quest Diagnos; 19/04/2018 – QUEST DIAGNOSTICS INC QTRLY REPORTED DILUTED EPS OF $1.27; 08/03/2018 MI WARN NOTICES: QUEST DIAGNOSTICS CUTS 57 JOBS ON CLOSING; 19/04/2018 – QUEST DIAGNOSTICS INC QTRLY ADJUSTED DILUTED EPS EXCLUDING AMORTIZATION OF $1.52; 14/03/2018 – Genomic Vision Extends Its Collaboration with Quest Diagnostics in Spinal Muscular Atrophy (SMA); 24/05/2018 – UnitedHealth: Quest Will Be In Network for All UnitedHealth Plan Participants Starting Jan. 1, 2019; 09/04/2018 – New Survey: False Beliefs about Sexual Risk, Poor Physician-Patient Communication May lmpede STD Screening in Young Women

Since January 2, 2018, it had 0 buys, and 16 sales for $55.61 million activity. Klug Robert A had sold 1,157 shares worth $119,932 on Friday, February 23. 83,669 shares were sold by Cohen Jon R, worth $8.72M. Shares for $517,322 were sold by Davis J. E.. The insider LEIDEN JEFFREY M sold 1,644 shares worth $173,623. Doherty Catherine T. sold 21,294 shares worth $2.21M. Shares for $18.03 million were sold by RUSCKOWSKI STEPHEN H on Friday, May 25. PREVOZNIK MICHAEL E had sold 1,423 shares worth $148,576.

Among 23 analysts covering Quest Diagnostics (NYSE:DGX), 12 have Buy rating, 1 Sell and 10 Hold. Therefore 52% are positive. Quest Diagnostics had 75 analyst reports since August 4, 2015 according to SRatingsIntel. Mizuho maintained Quest Diagnostics Incorporated (NYSE:DGX) on Thursday, October 22 with “Neutral” rating. RBC Capital Markets maintained Quest Diagnostics Incorporated (NYSE:DGX) on Friday, January 29 with “Sector Perform” rating. Raymond James downgraded the stock to “Market Perform” rating in Monday, September 25 report. Raymond James maintained the stock with “Buy” rating in Monday, June 26 report. The rating was maintained by SunTrust on Friday, October 13 with “Hold”. The rating was maintained by Robert W. Baird on Thursday, February 1 with “Hold”. The rating was maintained by Jefferies on Tuesday, June 27 with “Hold”. The stock has “Buy” rating by William Blair on Friday, June 8. The firm has “Underweight” rating by Morgan Stanley given on Thursday, August 10. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Hold” rating by Robert W. Baird on Sunday, November 12.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $15.03 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 19.72 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart